CORDIS - Forschungsergebnisse der EU
CORDIS

The first Integrated m-Health solution for anaphylaxis management.

Ziel

Adan Medical Innovation is a private company focused on the medical devices and the m-health solutions markets. We have patented an m-Health technology for anaphylaxis management, which consists on a smart case for an epinephrine auto-injector linked via Bluetooth to a medical mobile app. Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. The only adequate treatment is an immediate intramuscular epinephrine injection by using an auto-injector. However, patient self-management of auto-injectors has several problems: a) Need to check periodically drug condition, b) low adherence because patients forget carrying the auto-injector, c) difficulties to administer intramuscular epinephrine.
Adanmi has developed the first integrated solution to solve all these issues: a) The smart auto-injector case monitors epinephrine condition; b) The smartphone alerts distance from auto-injector in case the subject forgets it, c) during anaphylaxis it initiates an automated emergency protocol alerting contacts with exact GPS location and providing administration video-instructions.

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Koordinator

ADAN MEDICAL INNOVATION SL
Netto-EU-Beitrag
€ 50 000,00
Adresse
ANGLI 31 4 1
08017 BARCELONA
Spanien

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
Este Cataluña Barcelona
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 71 429,00